CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $22,243,304 | +23.8% | 699,695 | -5.0% | 0.04% | -2.5% |
| Q1 2023 | $17,963,748 | -46.5% | 736,521 | -30.8% | 0.04% | -69.2% |
| Q4 2022 | $33,571,208 | +1.7% | 1,064,401 | -8.9% | 0.13% | +21.5% |
| Q3 2022 | $33,024,000 | +3.1% | 1,168,596 | -3.5% | 0.11% | +24.4% |
| Q2 2022 | $32,018,000 | -46.1% | 1,210,979 | -28.7% | 0.09% | -27.7% |
| Q1 2022 | $59,426,000 | -4.0% | 1,697,376 | -11.1% | 0.12% | +3.5% |
| Q4 2021 | $61,891,000 | -32.9% | 1,909,035 | -38.9% | 0.12% | -26.3% |
| Q3 2021 | $92,230,000 | +36.0% | 3,126,435 | +18.1% | 0.16% | +56.0% |
| Q2 2021 | $67,801,000 | +182.2% | 2,646,435 | +51.2% | 0.10% | +177.8% |
| Q1 2021 | $24,028,000 | -17.2% | 1,750,000 | 0.0% | 0.04% | -23.4% |
| Q4 2020 | $29,015,000 | – | 1,750,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |